Edwin M Posadas1,2, Rafi S Ahmed1,2, Theodore Karrison3, Russell Z Szmulewitz4, Peter H O'Donnell4, James L Wade5, James Shen1,2, Murali Gururajan1, Margarit Sievert1, Walter M Stadler4. 1. Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. 2. Division of Hematology/Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. 3. Biostatistics, Department of Health Service, University of Chicago, Chicago, Illinois. 4. Genitourinary Oncology Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois. 5. Cancer Care Specialists of Central Illinois, S.C, Decatur, Illinois.
Abstract
BACKGROUND: Fyn is a kinase that is upregulated in a subset of metastatic castration-resistant prostate cancer. Saracatinib potently inhibits Fyn activation. We have noted a relationship between Fyn expression and directional motility, a cellular process related to metastasis. As such we hypothesized that treatment with saracatinib would increase the time required to develop new metastatic lesions. METHODS:Patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel were eligible for enrollment. This study was executed as a randomized discontinuation trial. During a lead-in phase of two 28-Day cycles, all patients received saracatinib. Afterward, patients with radiographically stable disease were randomized to either saracatinib or placebo. Patients continued treatment until evidence of new metastasis. RESULTS: Thirty-one patients were treated. Only 26% of patients had stable disease after 8 weeks and thus proceeded to randomization. This required early termination of the study for futility. The 70% of patients who progressed after the lead-in phase exhibited expansion of existing lesions or decompensation due to clinical progression without new metastatic lesions. Fatigue was reported in more than 25% of patients (all grades) with only two patients experiencing grade 3 toxicity. Other grade 3 adverse events included dehydration, thrombocytopenia, and weakness. CONCLUSIONS: This study was unable to determine if saracatinib had potential as metastasis inhibitor. Metastasis inhibition by saracatinib may still be viable in an earlier time in the disease history.
RCT Entities:
BACKGROUND:Fyn is a kinase that is upregulated in a subset of metastatic castration-resistant prostate cancer. Saracatinib potently inhibits Fyn activation. We have noted a relationship between Fyn expression and directional motility, a cellular process related to metastasis. As such we hypothesized that treatment with saracatinib would increase the time required to develop new metastatic lesions. METHODS:Patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel were eligible for enrollment. This study was executed as a randomized discontinuation trial. During a lead-in phase of two 28-Day cycles, all patients received saracatinib. Afterward, patients with radiographically stable disease were randomized to either saracatinib or placebo. Patients continued treatment until evidence of new metastasis. RESULTS: Thirty-one patients were treated. Only 26% of patients had stable disease after 8 weeks and thus proceeded to randomization. This required early termination of the study for futility. The 70% of patients who progressed after the lead-in phase exhibited expansion of existing lesions or decompensation due to clinical progression without new metastatic lesions. Fatigue was reported in more than 25% of patients (all grades) with only two patients experiencing grade 3 toxicity. Other grade 3 adverse events included dehydration, thrombocytopenia, and weakness. CONCLUSIONS: This study was unable to determine if saracatinib had potential as metastasis inhibitor. Metastasis inhibition by saracatinib may still be viable in an earlier time in the disease history.
Authors: Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte Journal: Proc Natl Acad Sci U S A Date: 2012-01-17 Impact factor: 11.205
Authors: Walter M Stadler; Gary Rosner; Eric Small; Donna Hollis; Brian Rini; S Donald Zaentz; John Mahoney; Mark J Ratain Journal: J Clin Oncol Date: 2005-06-01 Impact factor: 44.544
Authors: Ana R Jensen; Saito Y David; Chuanhong Liao; Jinlu Dai; Evan T Keller; Hikmat Al-Ahmadie; Kelly Dakin-Haché; Peter Usatyuk; Margarit F Sievert; Gladell P Paner; Soheil Yala; Gustavo M Cervantes; Viswanathan Natarajan; Ravi Salgia; Edwin M Posadas Journal: Clin Cancer Res Date: 2011-03-01 Impact factor: 12.531
Authors: Houjian Cai; Daniel A Smith; Sanaz Memarzadeh; Clifford A Lowell; Jonathan A Cooper; Owen N Witte Journal: Proc Natl Acad Sci U S A Date: 2011-04-04 Impact factor: 11.205
Authors: Edwin M Posadas; Hikmat Al-Ahmadie; Victoria L Robinson; Ramasamy Jagadeeswaran; Kristen Otto; Kristen E Kasza; Maria Tretiakov; Javed Siddiqui; Kenneth J Pienta; Walter M Stadler; Carrie Rinker-Schaeffer; Ravi Salgia Journal: BJU Int Date: 2008-10-16 Impact factor: 5.588
Authors: Primo N Lara; Jeff Longmate; Christopher P Evans; David I Quinn; Przemyslaw Twardowski; Gurkamal Chatta; Edwin Posadas; Walter Stadler; David R Gandara Journal: Anticancer Drugs Date: 2009-03 Impact factor: 2.248
Authors: William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg Journal: Clin Cancer Res Date: 2008-01-01 Impact factor: 12.531
Authors: Adam T Szafran; Cliff Stephan; Michael Bolt; Maureen G Mancini; Marco Marcelli; Michael A Mancini Journal: Prostate Date: 2016-10-04 Impact factor: 4.104
Authors: Indranil Chattopadhyay; Jianmin Wang; Maochun Qin; Lingqiu Gao; Renae Holtz; Robert L Vessella; Robert W Leach; Irwin H Gelman Journal: Oncotarget Date: 2017-02-07
Authors: Julia Rosemann; Lisa Müller; Jonas Weiße; Matthias Kappler; Alexander W Eckert; Markus Glaß; Danny Misiak; Stefan Hüttelmaier; Wolfgang G Ballhausen; Mechthild Hatzfeld; Monika Haemmerle; Tony Gutschner Journal: Mol Cancer Date: 2021-06-11 Impact factor: 27.401
Authors: Sarah Danson; Matthew R Mulvey; Lesley Turner; Janet Horsman; KJane Escott; Robert E Coleman; Sam H Ahmedzai; Michael I Bennett; David Andrew Journal: J Bone Oncol Date: 2019-09-18 Impact factor: 4.072